Mr. Bill Zhang reports

DRI HEALTHCARE ANNOUNCES EXERCISE OF PUT OPTION ON EKTERLY

DRI Healthcare Trust has exercised its contractual put option with respect to DRI Healthcare's royalty participation right in Ekterly (sebetralstat) for a total net repurchase price of approximately $178-million (U.S.).

The put option has been exercised in connection with the completion of Chiesi Group's acquisition of KalVista Pharmaceuticals Inc. on June 11, 2026. Subject to the terms of the royalty agreement, DRI Healthcare expects to receive payment no later than mid-August.

"We are pleased with the outcome of DRI Healthcare's first preapproval transaction. Exercising our put option at this juncture allows us to crystallize an attractive return for our unitholders. The proceeds represent a strong outcome for DRI Healthcare and reflect the quality of our underwriting," said Ali Hedayat, chief executive officer of DRI Healthcare.

"We congratulate Chiesi Group and KalVista on a transformative transaction. We look forward to redeploying these proceeds into the biopharmaceutical industry in a manner that generates long-term value for our unitholders," added Navin Jacob, chief investment officer of DRI Healthcare.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, it has deployed more than $3.0-billion, acquiring more than 75 royalties on 50-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in U.S. dollars under the symbol DHT.U.

We seek Safe Harbor.